Abstract
<jats:p>Objectives: Osteoarthritis is a painful and degenerative joint disease, without effective treatment options. We here determined therapeutic efficacy and mode-of-action of human induced pluripotent-derived therapeutic stem cells (hiMSCs) across in vivo mouse and ex vivo human osteoarthritis models. Methods: Therapeutic efficacy of hiMSCs with a thermosensitive hydrogel as carriers was assessed in mice with destabilization of the medial meniscus (DMM) for their effect in intact living joints, as well as in human osteoarthritic cartilage explants for their direct translational relevance on human osteoarthritic cartilage. Efficacy outcome measures of hiMSC treatment was assessed by histology and immunohistochemistry (Col2 and Mmp13) in DMM mouse model and by immunohistochemistry, bulk RNA-sequencing, and spatial transcriptomics (Xenium, 10X-Genomics, custom probe panel of 295 genes) in human cartilage explant model. Results: hiMSC treatment in DMM-mice significantly reduced OARSI damage scores, which was affirmed by a decrease in the catabolic marker Mmp13 and an increase in the anabolic marker Col2. These treatment effects appeared, irrespective of modifying factors such as xeno-free media or thermosensitive hydrogel carrier. Subsequently treatment of hiMSC+gel in human osteoarthritic cartilage explants showed a transcriptome-wide significant activation of the cholesterol (GO:PB0033490) and sterol (GO:BP0016126) synthesis pathways marked by genes such as MVD, DHCR7, MSMO1, FABP3. Additionally, we showed that these changes alleviated OA-associated imbalances of the cellular Zinc-ion homeostasis pathways (GO:BP0006882), represented by genes such as MT1F, MT1G, MT1H and SLC30A1. Spatial transcriptomics then sensitively captured that hiMSC+gel treatment evoked, specifically at the superficial cartilage layer, a consistent upregulation of healthy chondrocyte markers such as CHAD, ACAN, FRZB, and SOX9, alongside a suppression of catabolic and inflammatory mediators such as SERPINE1, SPP1, MMP13, ADAMTS5. Conclusions: Our findings link therapeutic outcomes of hiMSC treatment to precise spatially resolved molecular changes in human tissue, that would otherwise be obscured by heterogeneous cell populations. Collectively our study highlighted that hiPSC-derived stem cell therapy (hiMSCs) could provide a scalable off-the-shelf solution to treat osteoarthritis, with strong prospects for clinical applications in the near future.</jats:p>